aTyr PharmaATYR +10.36%14 Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus rates ATYR with a GF Score™ of 14/100 and a GF Value™ of $0.46 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 839 Biotechnology companies, aTyr Pharma ranks worse than 119189.39% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. aTyr Pharma's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. aTyr Pharma's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
aTyr Pharma Receivables Turnover Related Terms
aTyr Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for aTyr Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATYR vs DWTX, CNTX, INKT: Receivables Turnover Comparison
For the Biotechnology subindustry, aTyr Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma (ATYR) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on aTyr Pharma and its competitors. According to the industry distribution chart, aTyr Pharma ranks #999999 out of 839 companies in the Biotechnology industry.
Is aTyr Pharma's Receivables Turnover too high?
aTyr Pharma's current Receivables Turnover is 0.00. Based on the distribution chart, aTyr Pharma ranks #999999 out of 839 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's Receivables Turnover compare to DWTX and CNTX?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #999999 out of 839 companies for Receivables Turnover. This places aTyr Pharma in the lower half of its industry. The industry median Receivables Turnover is 5.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on aTyr Pharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. aTyr Pharma's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.46, compared to a current price of $0.65 — trading 42.3% above its estimated fair value. The current Receivables Turnover is 0.00. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aTyr Pharma (ATYR) Overvalued in 2026?
Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued.
The current stock price of $0.65 is trading 42.3% above its estimated GF Value™ of $0.46.
GuruFocus considers aTyr Pharma to be Significantly Overvalued.
Key valuation signals for ATYR:
Receivables Turnover: 0.00
GF Value™: $0.46 vs. price of $0.65 (42.3% above fair value)
No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score
Get the complete analysis for ATYR
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATYR has been successfully added to your 
